Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XY0206 in Chinese Advanced or Metastatic Solid Tumors
NCT03658070Phase 1Unknown
- Sponsor
- Yiling Pharmaceutical
- Start
- Dec 2018
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of XY0206 in solid tumor (advanced stage), sponsored by Yiling Pharmaceutical. Primary endpoints: Dose Limiting Toxicity at 28 days and Adverse Events. Status: unknown.
02
Drugs
XY0206
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03658070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03658070.